CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence

Area of Science:

• Immunotherapy
• Gene Editing Technology
• Oncology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy is an emerging strategy for malignant tumors with improved efficacy over the past decade.
• Despite advancements, CAR-T therapy faces limitations, particularly in solid tumors, and relapse occurs in hematologic malignancies due to poor CAR-T cell expansion and persistence.

Purpose of the Study:

• To describe factors limiting CAR-T cell persistence in patients.
• To discuss the application of CRISPR/Cas9 technology in enhancing CAR-T cell persistence and anti-tumor function.
• To review clinical trials involving CRISPR/Cas9-engineered CAR-T cells for cancer treatment.

Main Methods:

• Review of current literature on CAR-T cell therapy limitations.
• Analysis of CRISPR/Cas9 applications for CAR-T cell enhancement (e.g., generating memory phenotype, reducing exhaustion, screening targets).
• Investigation of ongoing and completed clinical trials for CRISPR/Cas9-modified CAR-T cells.

Main Results:

• Identified poor expansion and persistence as key limitations of CAR-T cell therapy.
• Highlighted CRISPR/Cas9's potential to improve CAR-T cell proliferation, persistence, and anti-tumor activity.
• Noted the increasing number of clinical trials exploring CRISPR/Cas9-engineered CAR-T cells.

Conclusions:

• CRISPR/Cas9 technology offers a promising approach to overcome CAR-T cell persistence issues.
• Enhancing CAR-T cell persistence through gene editing can improve therapeutic outcomes in various cancers.
• Further clinical investigation of CRISPR/Cas9-modified CAR-T cells is warranted to optimize cancer treatment strategies.